From their meeting in March, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has published the highlights. Read more “Highlights from the March CHMP meeting 2020”
Category: Industry news
The latest news from the Pharmaceutical Industry
Further information on how to manage clinical trials during the pandemic
The Medicines and Healthcare products Regulatory Agency (MHRA) have now released guidance on how investigators and sponsors should manage clinical trials during COVID-19. Read more “Further information on how to manage clinical trials during the pandemic”
Coronavirus-induced drug and device shortages
As the novel coronavirus outbreak continues to spread across the globe, Europe and the US are bracing for disruption to the medicine supply chain. Read more “Coronavirus-induced drug and device shortages”
Brexit done: more information on the regulatory challenges that await
After years of waiting and wondering, the UK has finally left the EU. So, in the short term, how will the regulatory and drug safety environment change, and what will stay the same?
Read more “Brexit done: more information on the regulatory challenges that await”
Pilot for Reporting Illicit Drug Reactions to be discontinued
Public Health England (PHE) have decided to close the 2017 Reporting Illicit Drug Reactions (RIDR) pilot programme by 28 February 2020. Read more “Pilot for Reporting Illicit Drug Reactions to be discontinued”
EMA Management Board meeting highlights the upcoming challenges in 2020
Following three years of relocation and workforce changes, the European Medicines Agency has outlined the challenges to come, in its December Management Board meeting. Read more “EMA Management Board meeting highlights the upcoming challenges in 2020”
What is the benefit of the FDA’s new app for reporting novel uses of infectious disease drugs?
The United States (US) Food and Drug Administration (FDA) have launched an application (app) for global health-care professionals (HCPs) to report novel uses of existing medicine for patients with rare and difficult-to-treat infectious diseases. Read more “What is the benefit of the FDA’s new app for reporting novel uses of infectious disease drugs?”
New “smart pill” technology shows 100% success rate
A new “smart pill” bottle which prompts patients to take their medications on time and notifies doctors when it has been dispensed, has shown 100% reliability in improving medication adherence. Read more “New “smart pill” technology shows 100% success rate”
The need for cross-sectoral, global cooperation to fight antimicrobial resistance
The statement emphasises the role of medicines regulators in efficiently bringing safe, effective and high quality antimicrobial products to the market, as well as minimising the regulatory barriers which can prevent access to essential treatments. Read more “The need for cross-sectoral, global cooperation to fight antimicrobial resistance”
The latest advancements on the use of artificial intelligence in drug development
Approximately 50% of late-stage clinical trials fail due to ineffective drug targets, meaning only 15% of drugs advance from Phase II trials to approval. Artificial intelligence (AI) can help to enhance drug development by making more accurate predictions in novel areas of biology and chemistry. Read more “The latest advancements on the use of artificial intelligence in drug development”